|4.09||-0.01 / -0.24%|
Data as of 4:00pm ET
|4.09||-0.0002 / -0.00%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 11.50, with a high estimate of 12.00 and a low estimate of 11.00. The median estimate represents a +181.17% increase from the last price of 4.09.
The current consensus among 3 polled investment analysts is to Buy stock in ZIOPHARM Oncology Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.